Palifosfamide
| Title | Journal |
|---|---|
| Pharmacokinetics of TH-302: a hypoxically activated prodrug of bromo-isophosphoramide mustard in mice, rats, dogs and monkeys. | Cancer chemotherapy and pharmacology 20120301 |
| Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin. | Anti-cancer drugs 20120201 |
| The effect of N-acetylcysteine on the antitumor activity of ifosfamide. | Canadian journal of physiology and pharmacology 20110501 |
| Ifosfamide metabolites CAA, 4-OH-Ifo and Ifo-mustard reduce apical phosphate transport by changing NaPi-IIa in OK cells. | Kidney international 20061101 |
| [Identification of glufosfamide metabolites in rats]. | Yao xue xue bao = Acta pharmaceutica Sinica 20060601 |
| Comparative preclinical toxicology and pharmacology of isophosphoramide mustard, the active metabolite of ifosfamide. | Cancer chemotherapy and pharmacology 20050201 |
| 1,3- vs 1,5-intramolecular alkylation reactions in isophosphoramide and phosphoramide mustards. | Chemical research in toxicology 20040901 |
| Phosphate prodrugs of isophosphoramide mustard. | Acta poloniae pharmaceutica 20030101 |
| Isophosphoramide mustard analogues as prodrugs for anticancer gene-directed enzyme-prodrug therapy (GDEPT). | Acta biochimica Polonica 20020101 |
| Mechanisms of resistance against cyclophosphamide and ifosfamide: can they be overcome without sacrificing selectivity? | Cancer treatment and research 20020101 |
| Identification of new aqueous chemical degradation products of isophosphoramide mustard. | Journal of pharmaceutical and biomedical analysis 20010601 |
| Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma. | Lancet (London, England) 19800927 |